Episode 7 - Science, PhRMA campaign and new discoveries and J&J’s R&D productivity stop gap M&A

January 31, 2017

In this episode, I discuss the new Pfizer campaign around scientists as well as Martin Shkreli's response to the Davos comments.  Then we discuss J&J's move to acquire Actelion and more importantly, their decision to spin off the R&D unit to be independent.  Near the end, discussion around scientific discoveries in the area of CAR-T treatment of two babies and new findings in breast cancer including drug resistance and passive/backseat genes that manipulate the cancer progression.

00:0000:00

Facebook Comments: